Miranda C. Lahman

Miranda C. Lahman

Auto-generated profile, based on publicly available information

Miranda C. Lahman

Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
MLMiranda C. Lahman
Miranda C. Lahman
TSThomas M. Schmitt
Thomas M. Schmitt
KPKelly G. Paulson
Kelly G. Paulson
NVNathalie Vigneron
Nathalie Vigneron
DBDenise Buenrostro
Denise Buenrostro
PGPhilip D. Greenberg
Philip D. Greenberg
Designing effective antileukemic immunotherapy will require understanding mechanisms underlying tumor control or resistance. Here, we report a mechanism of escape from immunologic targeting in an acute myeloid leukemia (AML) patient, who relapsed 1 year after immunotherapy with engineered T cells expressing a human leukocyte antigen A*02 (HLA-A2)–restricted T cell receptor (TCR) specific for a Wilms’ tumor antigen 1 epitope, WT1 126–134 (T TCR-C4 ). Resistance occurred despite persistence of functional therapeutic T cells and continuous expression of WT1 and HLA-A2 by the patient’s AML cells. Analysis of the recurrent AML revealed expression of the standard proteasome, but limited expression of the immunoproteasome, specifically the beta subunit 1i (β1i), which is required for presentation of WT1 126–134 . An analysis of a second patient treated with T TCR-C4 demonstrated specific loss of AML cells coexpressing β1i and WT1. To determine whether the WT1 protein continued to be processed and presented in the absence of immunoproteasome processing, we identified and tested a TCR targeting an alternative, HLA-A2–restricted WT1 37–45 epitope that was generated by immunoproteasome-deficient cells, including WT1-expressing solid tumor lines. T cells expressing this TCR (T TCR37–45 ) killed the first patients’ relapsed AML resistant to WT1 126–134 targeting, as well as other primary AML, in vitro. T TCR37–45 controlled solid tumor lines lacking immunoproteasome subunits both in vitro and in an NSG mouse model. As proteasome composition can vary in AML, defining and preferentially targeting these proteasome-independent epitopes may maximize therapeutic efficacy and potentially circumvent AML immune evasion by proteasome-related immunoediting.

13 April 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MLMiranda C. Lahman
Miranda C. Lahman
KPKelly G. Paulson
Kelly G. Paulson
PNPeter P. Nghiem
Peter P. Nghiem
ACAude G. Chapuis
Aude G. Chapuis